VIR - Company ID 0001706431
Vir Biotechnology, Inc. trades as VIR and has a market capitalization of $1.75 B, making it the #2254 largest US-listed company by market value. In its fiscal 2025 annual report the company posted revenue of $68.56M, down 7.6% from the prior year and net income of -$437.99M. This page tracks Vir Biotechnology, Inc. through 762 SEC filings, with financial statements and metrics updated as new reports are filed.
Research snapshot
Updated
2026-07-09
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
Next research step
Over the last 8 fiscal years Vir Biotechnology, Inc.'s revenue grew from $2.71M to $68.56M, a compound annual growth rate of 49.8%. Net profit margin expanded from -2579.5% to -638.9% over the same period - every figure below comes from the company's audited annual filings.
Dig into the full income statement, balance sheet, and cash flow statement with annual and quarterly views.
| Filing | Type | Filed |
|---|---|---|
| SCHEDULE 13G/A | - | 2026-05-15 |
| Quarterly report | 10-Q | 2026-05-07 |
| Major company event | 8-K | 2026-05-06 |
| Insider trade | 4 | 2026-05-04 |
| Insider sale notice | 144 | 2026-04-30 |
| Insider trade | 4 | 2026-04-30 |
| SCHEDULE 13G | - | 2026-04-29 |
| Proxy materials | DEFA14A | 2026-04-16 |
- Confidential & Anonymous Financial Concern Hotline
- Confidential & Anonymous Financial Concern Hotline
- Confidential & Anonymous Financial Concern Hotline
- Confidential & Anonymous Financial Concern Hotline
- Confidential & Anonymous Financial Concern Hotline
The largest companies sharing Vir Biotechnology, Inc.'s SEC industry classification (biological products, (no diagnostic substances)).
Vir Biotechnology, Inc. (VIR) has a market capitalization of $1.75 B as of 2026-07-09, ranking #2254 among US-listed companies.
Vir Biotechnology, Inc. reported revenue of $68.56M for fiscal year 2025, a decrease of 7.6% year over year.
In its latest fiscal year Vir Biotechnology, Inc. reported a net loss of $437.99M.